4 / 10
allied
academies
Page 20
Notes:
Journal of Infectious Diseases and Medical Microbiology | Volume 3
November 11-12, 2019 | Singapore
International Conference on
3
rd
International Conference on
Pathology and Infectious Diseases
Pathology and Oncology Research
Joint Event
&
J Infectious Disease Med Microbiol
| Volume 3
Pseudoprogression under checkpoint inhibition therapy
Mona Passler
Charité - University Medicine, Germany
A
novel agent called checkpoint inhibitor therapy has
revolutionized not only the treatment for several tumor
entities but also our general understanding of oncology.
As more and more patients with solid tumors undergo
this promising immune therapy, new phenomena like
pseudoprogression challenge the clinician.
Pseudoprogression is a temporary increase in tumor size
due to infiltrating leucocytes and edema during checkpoint
inhibitortherapy,whichcanbemistakenwithrealprogression.
Subsequently, tumor size decreases due to tumor cell
destruction. Pseudoprogression is described in 1.5% - 17% of
allcases-dependingonthetumorentityandstudy.Identifying
pseudoprogression plays a decisive part in successfully using
checkpoint inhibition therapy, because the misinterpretation
of tumor growth might lead to the discontinuation of an
effective treatment, as pseudoprogression indicates a
high likelihood of > 1year survival. In order to guarantee
the best possible treatment, it is crucial to be informed
about pseudoprogression and to know techniques to
distinguish between pseudo- and real progression when
tumor size increases under checkpoint inhibition therapy.
While there are several indicators to differentiate between
the two, ultimately only infiltrating growth – which solely
occurs in malign tumor growth – proves real progression.
Speaker Biography
Mona Passler graduated from Charité Medical University, Berlin, Germany.
She is a junior researcher and has worked for several years with Dr. Pietzner
and Professor Sehouli from Charité University Berlin specializing with
malignant ascites in ovarian cancer and checkpoint inhibition therapy.
e:
mona.passler@charite.de